Eupraxia Pharmaceuticals (EPRX) Cash from Investing Activities (2023 - 2026)
Eupraxia Pharmaceuticals' (EPRX) quarterly Cash from Investing Activities came in at -$80.1 million in Q1 2026, down 47255.43% year-on-year from N/an in Q1 2025, and down 41312.88% on a QoQ basis from -$193301.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 4 years of Cash from Investing Activities data on file, last reported at -$80.1 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 47255.43% year-over-year to -$80.1 million in Q1 2026; TTM through Mar 2026 was -$80.5 million, a 33794.98% decrease from a year earlier, with the FY2025 full-year figure at -$588947.0, down 683.6% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$80.1 million, down from -$193301.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for EPRX reached as high as $17662.0 in Q2 2024 and fell as low as -$80.1 million in Q1 2026.
- Historically, Cash from Investing Activities has averaged -$6.2 million across 4 years, with a median of -$43757.0 in 2024.
- Across the five-year window, Cash from Investing Activities soared 379.37% in 2024 and sank 47255.43% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$49385.0 in 2023, then climbed by 11.4% to -$43757.0 in 2024, then tumbled by 341.76% to -$193301.0 in 2025, then plunged by 41312.88% to -$80.1 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$80.1 million in Q1 2026, -$193301.0 in Q4 2025, and -$60377.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Eupraxia Pharmaceuticals | 346.51 Mn | 346.51 Mn | - | -80.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80.05 Mn |
| Mar 31, 2026 | -80.05 Mn |
| Dec 31, 2025 | -193,301.00 |
| Dec 31, 2025 | -193,301.00 |
| Sep 30, 2025 | -60,377.00 |
| Sep 30, 2025 | -60,377.00 |
| Jun 30, 2025 | -166,225.00 |
| Jun 30, 2025 | -166,225.00 |
| Mar 31, 2025 | -169,044.00 |
| Mar 31, 2025 | -169,044.00 |
| Dec 31, 2024 | -43,757.00 |
| Dec 31, 2024 | -43,757.00 |
| Sep 30, 2024 | -42,275.00 |
| Sep 30, 2024 | -42,275.00 |
| Jun 30, 2024 | 17,662.00 |
| Jun 30, 2024 | 17,662.00 |
| Mar 31, 2024 | -6,789.00 |
| Mar 31, 2024 | -6,789.00 |
| Dec 31, 2023 | -49,385.00 |
| Dec 31, 2023 | -49,385.00 |